ANI Pharmaceuticals updates investor deck for conferences

ANI Pharmaceuticals, Inc. filed a current report noting that President & CEO Nikhil Lalwani and the executive leadership team will present at two upcoming investor conferences in New York City.

Rhea-AI Filing Summary

ANI Pharmaceuticals, Inc. filed a current report noting that President & CEO Nikhil Lalwani and the executive leadership team will present at two upcoming investor conferences in New York City. They are scheduled to speak at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025.

The company prepared an updated investor presentation for these events, dated September 2025, and may use it in future meetings with investors and analysts. This presentation is provided as Exhibit 99.1 and is furnished, rather than filed, meaning it is not subject to certain liability provisions under securities laws unless specifically incorporated into other filings.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event does ANI Pharmaceuticals (ANIP) disclose in this 8-K?

The company discloses that its President & CEO Nikhil Lalwani and members of the executive leadership team will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, in New York City.

What new material does ANI Pharmaceuticals (ANIP) make available to investors?

ANI Pharmaceuticals provides an updated investor presentation dated September 2025, attached as Exhibit 99.1, which may be used in meetings with investors and analysts.

Is the ANI Pharmaceuticals investor presentation considered filed with the SEC?

The investor presentation furnished as Item 2.02 and Exhibit 99.1 is explicitly stated as not being deemed “filed” for purposes of Section 18 of the Exchange Act, and it is not subject to those liabilities unless specifically incorporated by reference in another filing.

Who signed the ANI Pharmaceuticals (ANIP) 8-K report?

The report was signed on behalf of ANI Pharmaceuticals, Inc. by Stephen P. Carey, Senior Vice President Finance and Chief Financial Officer, dated September 8, 2025.

What is the purpose of the ANI Pharmaceuticals investor presentations at these conferences?

The filing explains that the company’s leadership will present at the conferences and may use the updated investor presentation in various meetings with investors and analysts, providing them with current information about ANI Pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/08/2025 - 06:57 AM Learn about SEC filing dates

0001023024FALSE00010230242025-09-082025-09-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): September 8, 2025

ANI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-31812			58-2301143
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

210 Main Street West Baudette, Minnesota			56623
(Address of principal executive offices)			(Zip Code)

Registrant's telephone number, including area code: (218) 634-3500

Not Applicable

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock			ANIP			Nasdaq Stock Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition

Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, Inc., along with members of the Company’s executive leadership team, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, in New York City, and is providing an updated investor presentation. The Company may use the updated investor presentation in various meetings with investors and analysts from time to time. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*

Item 7.01 Regulation FD Disclosure

The information included under Item 2.02 of this Current Report on Form 8-K is incorporated into this Item 7.01 by reference.*

Item 9.01 Exhibits

(d)Exhibits

Exhibit No.			Description
99.1			Investor Presentation, dated September 2025
104			Cover Page Interactive Data File (embedded with the Inline XBRL document)

*The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 8, 2025			ANI PHARMACEUTICALS, INC.
			By:			/s/ Stephen P. Carey
			Name:			Stephen P. Carey
			Title:			Senior Vice President Finance and Chief Financial Officer